ALAobo Li

Aobo Li

*This is an algorithmically generated author record based on publicly available information.

Aobo Li has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of Direct‐Acting Oral Anticoagulants in Atrial Fibrillation With Hypertrophic Cardiomyopathy

    by Amro Taha, Avilash Mondal, Usman Ali Akbar, Aobo Li, Harigopal Sandhyavenu, Mohamed Alhajji, Sittinun Thangjui, Harshith Thyagaturu, Christopher Bianco, Marco Caccamo, et al.

    Background: Patients with hypertrophic cardiomyopathy (HCM) were excluded from pivotal trials comparing the efficacy and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists. Methods: Our retrospective cohort study using the TriNetX database compared adults with HCM‐atrial fibrillation who initiated DOACs or vitamin K antagonists. The primary outcomes were all‐cause mortality and ischemic stroke/systemic thromboembolism. Secondary outcomes included major bleeding, intracranial hemorrhage, gastrointestinal bleeding, and all‐cause hospitalization. Subgroup analysis was conducted for obstructive HCM. Results: Among 13 143 patients with HCM‐atrial fibrillation (2963 matched pairs). DOAC use was associated with lower all‐cause mortality (hazard ratio [HR], 0.82[ 95% CI, 0.73–0.93]; P P =0.03), and intracranial hemorrhage (HR, 0.54 [95% CI, 0.36–0.79]; P =0.001) compared with vitamin K antagonists. No differences were observed in the rates of ischemic stroke (HR, 0.94 [95% CI, 0.73–1.2]; P =0.6) or the composite of stroke or systemic thromboembolism (HR, 0.87 [95% CI, 0.69–1.10]; P =0.25), gastrointestinal bleeding (HR, 0.97 [95% CI, 0.77–1.22]; P =0.82), or all‐cause hospitalizations (HR, 1.07 [95% CI, 0.93–1.07]; P =0.051). In the subgroup with obstructive HCM, DOAC use was associated with a reduced risk of all‐cause mortality (HR, 0.80 [95% CI, 0.66–0.99]; P =0.035) and major bleeding (HR, 0.76 [95% CI, 0.61–0.96]; P =0.02) without stroke or thromboembolic risk reduction (HR, 0.69 [95% CI, 0.47–1.01]; P =0.05). Conclusions: Among patients with HCM‐atrial fibrillation, DOACs were associated with lower mortality and bleeding risk compared with vitamin K antagonists, with no increased risk of stroke or systemic thromboembolism.

  • Open Access

    Trimetazidine suppresses oxidative stress, inhibits MMP‐2 and MMP‐9 expression, and prevents cardiac rupture in mice with myocardial infarction

    by Wei Gong, Youcai Ma, Aobo Li, Han Shi, Shaoping Nie

    Summary: Background/Aims: Cardiac rupture (CR) is a catastrophic complication of acute myocardial infarction (MI). At present, there are no effective pharmacological strategies for preventing post‐MI rupture. Here we investigated the effect of trimetazidine (TMZ) on post‐MI CR.Methods: MI models were induced by left coronary artery ligation in male C57BL/6 mice. Animals allocated to the rupture incidence were closely monitored for 7 days; autopsy was performed once animals were found dead to determine the reason of death. Heart function was detected by echocardiography. Oxidative stress markers and matrix metalloproteinases (MMPs) were analyzed by Western Blotting.Results: TMZ markedly reduced the post‐MI CR incidence of mice. We found that the expression of metalloproteinase (MMP) ‐2 and MMP‐9 in the TMZ‐treated group was significantly lower than the saline‐treated group. Further, TMZ markedly attenuated MI‐induced oxidative stress. To investigate the mechanism of the effect of TMZ on CR, we pretreated H9c2 cells with H2O2 and found that TMZ treatment markedly decreased H2O2‐induced MMP‐2 and MMP‐9 expression. TMZ prevents CR through inhibition of oxidative stress, which is attributable to the down‐regulation of MMP‐2, MMP‐9 expression.Conclusions: Our findings indicate that TMZ suppresses oxidative stress, inhibits MMP‐2 and MMP‐9 expression, and prevents CR in mice with MI.